Gemcitabine HCl Oral Formulation

DRUG2 trials

Sponsors

InnoPharmax Inc.

Conditions

Advanced Solid MalignanciesMalignant LymphomasMalignant Tumors

Early Phase 1

An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors

CompletedNCT01678690

InnoPharmax Inc.Malignant Tumors

Start: 2012-08-31End: 2014-04-30Updated: 2016-09-02

Phase 1

Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas

CompletedNCT01800630

InnoPharmax Inc.Advanced Solid Malignancies, Malignant Lymphomas

Start: 2013-04-30End: 2016-03-31Updated: 2019-07-08

Related Papers

Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.

Journal of Clinical Oncology2023-06-01

An open-label, exploratory, limited dose escalation study to evaluate the pharmacokinetics, safety and tolerability of gemcitabine hydrochloride oral formulation in subjects with malignant tumors.

Journal of Clinical Oncology2015-05-20

Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2014-05-20